Trial Profile

A Phase 3 study of PRT120 oral therapy for peanut allergy.

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 19 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs PRT 120 (Primary)
Indications Peanut hypersensitivity
Focus Registrational; Therapeutic Use
Sponsors Prota Therapeutics

Most Recent Events

19 Jan 2024 New trial record
16 Jan 2024 According to a Prota Therapeutics media release, company announced financing of US$21 million in equity and debt financing. the round, led by Singapore-based SPRIM Global Investments (SGI), will help the company prepare for a Phase 3 clinical investigation of the company's PRT120 oral therapy for peanut allergy.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com